Suzetrigine 50 mg · oral tablet
Analgesics
Approved uses
Moderate to severe acute pain, including post-operative pain
100 mg orally as the starting dose on an empty stomach, then starting 12 hours later, 50 mg every 12 hours with or without food, for the shortest duration consistent with individual patient treatment goals
A selective NaV1.8 blocker: not an opioid, no addiction liability, which is the reason to reach for it first
Contraindications
Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated.
50 mg tablets, bottles of 30 and 100, 100-count hospital unit dose pack
Suzetrigine is a selective blocker of the Na V 1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (Na V 1.1 through 1.9). Na V 1.8 is expressed in peripheral sensory neurons including dorsal root ganglion neurons, where its role is to transmit pain signals (action potentials). By selectively inhibiting Na V 1.8 channels, suzetrigine inhibits transmission of pain signals to the spinal cord and brain. M6-SUZ, a major active metabolite, is a less potent inhibitor of Na V 1.8 than suzetrigine by 3.7-fold.
Warnings & Precautions
- Adverse reactions with CYP3A inhibitors: Strong and moderate CYP3A inhibitors increase suzetrigine and M6-SUZ (active metabolite) exposures, which may cause JOURNAVX adverse reactions. Concomitant use of JOURNAVX with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dosage with moderate CYP3A inhibitors.
- Risk of drug interactions with certain CYP3A substrates: Suzetrigine is an inducer of CYP3A. If JOURNAVX is used with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage adjustment of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX.
- Interactions with certain hormonal contraceptives: Patients taking hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use additional nonhormonal contraceptives (such as condoms) or use alternative contraceptives (e.g., a combined oral contraceptive containing ethinyl estradiol as the estrogen and levonorgestrel or norethindrone as the progestin, an intrauterine system) during JOURNAVX treatment and for 28 days after discontinuation of JOURNAVX.
- Adverse reactions in hepatic impairment: Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and M6-SUZ (active metabolite), which may increase the risk of JOURNAVX related adverse reactions. Avoid use of JOURNAVX in patients with severe hepatic impairment (Child-Pugh Class C). The recommended JOURNAVX dosage is lower in patients with moderate hepatic impairment (Child-Pugh Class B).
Common Side Effects
The most common adverse reactions (greater incidence in JOURNAVX-treated patients compared to placebo-treated patients) were pruritus, muscle spasms, increased creatine phosphokinase, and rash.
Pregnancy: There are no available data on the use of JOURNAVX during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In rats, effects on implantation and maintenance of pregnancy occurred at oral suzetrigine doses of 2.2 times the maximum recommended human dose (MRHD) or more. In a pre- and postnatal development study, reduced mean gestation length and increased postnatal pup mortality were observed at maternal rat exposures of 1.6-times the MRHD. No malformations were observed when suzetrigine was administered orally to rats and rabbits during the period of organogenesis at doses up to 2.2- and 5.9-times, respectively, the MRHD. The clinical relevance of these findings is unclear.
Lactation: There are no data on the presence of suzetrigine or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Suzetrigine is present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for JOURNAVX and any potential adverse effects on the breastfed child from JOURNAVX or from the underlying maternal condition.
The safety and effectiveness of JOURNAVX has not been established in pediatric patients.